UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

Wed, 16 Sep 2026 08:47:42 -0400

UBS analyst David Dai reiterated a Buy rating and $33.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented, "SMMT/Akeso presented full HARMONi-2 and HARMONi data at WCLC yesterday, giving investors detailed looks at the KM curves and subgroup analyses. We think the full dataset continue to support ivonescimab's benefit in PD-L1+ NSCLC and EGFR+ NSCLC."

For an analyst ratings summary and ratings history on Summit Therapeutics plc click here. For more ratings news on Summit Therapeutics plc click here.

Shares of Summit Therapeutics plc closed at $17.40 yesterday.

Form 8-K Summit Therapeutics Inc. For: Sep 15

Tue, 15 Sep 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260915/27061855.html

Summit ivonescimab shows consistent survival data across regions at WCLC

Tue, 15 Sep 2026 06:01:44 -0400

Summit Therapeutics Inc. (Nasdaq: SMMT) presented updated overall survival data from its Phase III HARMONi clinical trial at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer in Seoul, South Korea.

The trial evaluates ivonescimab, an investigational bispecific antibody, combined with platinum-doublet chemotherapy versus placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who previously received a third-generation EGFR tyrosine kinase inhibitor.

In a June 2026 data cut, the global intention-to-treat population showed an overall survival hazard ratio of 0.76 (95% CI: 0.61–0.95; nominal p=0.0151), compared with a

Summit ivonescimab shows consistent survival data across regions at WCLC

Tue, 15 Sep 2026 06:01:44 -0400

In a June 2026 data cut, the global intention-to-treat population showed an overall survival hazard ratio of 0.76 (95% CI: 0.61–0.95; nominal p=0.0151), compared with a

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

Tue, 15 Sep 2026 06:00:00 -0400

Sustained OS Improvement Seen with Longer Follow-Up in Western Patients, Consistent across Geographic Regions; No New Safety Signals Observed

Akeso-Sponsored HARMONi-2 OS Data Also Presented at WCLC 2026; Additional Data from Landmark China-Only Study Included Herein

MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea.

As Summit previously

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

Tue, 15 Sep 2026 06:00:00 -0400

Sustained OS Improvement Seen with Longer Follow-Up in Western Patients, Consistent across Geographic Regions; No New Safety Signals Observed

Akeso-Sponsored HARMONi-2 OS Data Also Presented at WCLC 2026; Additional Data from Landmark China-Only Study Included Herein

As Summit previously

Form 8-K Summit Therapeutics Inc. For: Sep 13

Mon, 14 Sep 2026 08:38:00 -0400

si-local-file:///var/storage/secattach/20260914/27055975.html

Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer

Sun, 13 Sep 2026 19:47:17 -0400

Summit Therapeutics (NASDAQ: SMMT) announced that its partner Akeso Inc. (HKEX: 9926.HK) presented updated overall survival data from the Phase III HARMONi-2 trial at the International Association for the Study of Lung Cancer's 2026 World Conference on Lung Cancer in Seoul, South Korea.

The trial evaluated ivonescimab monotherapy against pembrolizumab monotherapy in 398 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expression. At a median follow-up of 36 months, ivonescimab produced a median overall survival of 30.8 months compared to 22.6 months for pembrolizumab, a difference of 8.2 months. The overall survival hazard ratio was

Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer

Sun, 13 Sep 2026 19:47:17 -0400

Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer

Sun, 13 Sep 2026 19:47:17 -0400

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study

Sun, 13 Sep 2026 07:00:00 -0400

Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab

HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months

PD-L1 High Expression Subgroup: Hazard Ratio = 0.58

Summit is Conducting Global Phase III HARMONi-7 Study in Patients with PD-L1 High-Expressing NSCLC

MIAMI--(BUSINESS WIRE)-- Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab is being presented at the International Association for the Study

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study

Sun, 13 Sep 2026 07:00:00 -0400

Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab

HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months

PD-L1 High Expression Subgroup: Hazard Ratio = 0.58

Summit is Conducting Global Phase III HARMONi-7 Study in Patients with PD-L1 High-Expressing NSCLC

Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy

Wed, 09 Sep 2026 06:45:42 -0400

Jefferies analyst Faisal Khurshid upgraded Summit Therapeutics plc (NASDAQ: SMMT) from Hold to Buy with a price target of $25.00 (from $15.00).

The analyst comments "We move to BUY ahead of H3 PFS data late '26. We think PFS likely to hit stats barring outlier degradation from China to global trial and most scenarios drive confidence in a downstream OS win. Our report includes an analysis of stats plans and China/global comps: we think PFS HR 0.65-0.70 is likely and points to a 1H27 OS win, while <0.75 still a win. We're believers in the MOA after pos OS in H6,

Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy

Wed, 09 Sep 2026 06:45:42 -0400

Jefferies analyst Faisal Khurshid upgraded Summit Therapeutics plc (NASDAQ: SMMT) from Hold to Buy with a price target of $25.00 (from $15.00).

Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy

Wed, 09 Sep 2026 06:45:42 -0400

Jefferies analyst Faisal Khurshid upgraded Summit Therapeutics plc (NASDAQ: SMMT) from Hold to Buy with a price target of $25.00 (from $15.00).

Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy

Wed, 09 Sep 2026 06:45:42 -0400

Jefferies analyst Faisal Khurshid upgraded Summit Therapeutics plc (NASDAQ: SMMT) from Hold to Buy with a price target of $25.00 (from $15.00).

UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

Tue, 08 Sep 2026 09:12:11 -0400

UBS analyst David Dai reiterated a Buy rating and $33.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented, "The 2H26 HARMONi-3 squamous NSCLC readout is the most important catalyst for SMMT and the most important global test of the PD- (L)1×VEGF class to date with potential read-through implications for BNTX/BMY, MRK, PFE, and ABBV. Based on our enrollment and event-accrual analysis, we expect a September-to-October cut-off and a 4Q26 readout, and believe investors are looking for PFS hazard ratio (HR) of <0.70 and supportive OS trends. Our base case assumes 5-30% ex-China efficacy degradation vs. HARMONi-6, resulting in

H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)

Thu, 03 Sep 2026 06:57:11 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Neutral rating on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented: "HARMONi-2’s interim overall survival win leaves our view unchanged without revelation of the hazard ratio. Akeso’s (9926.HK; not rated) 398-patient China Phase 3 HARMONi-2 met its prespecified interim OS key secondary endpoint for ivo 20mg/kg Q3W monotherapy vs. Merck’s (MRK; not rated) pembro 200mg Q3W in 1L PD-L1 TPS ≥1% advanced NSCLC. The study previously produced mPFS of 11.14 vs. 5.82 months and a PFS HR of 0.51. Akeso did not disclose the OS HR, medians, event count or maturity, 95% CI,

Summit Therapeutics plc (SMMT) Reiterated at Overweight by Cantor Fitzgerald

Tue, 01 Sep 2026 06:54:00 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented, "There are plenty of parallels between SMMT and MRNA. Both are stocks that many investors love to hate, both companies are seeking to overturn medical dogma, both are run by maverick CEOs. Another similarity is investor skepticism toward existing clinical datasets. Well before MRNA's intismeran autogene (personalized cancer vaccine) was shown to work in Phase 3, there was compelling randomized Phase 2 data that some chose to ignore. Similarly, we think the clinical evidence in support of SMMT's ivonescimab (PD-1 x VEGF bispecific)

Form 8-K Summit Therapeutics Inc. For: Aug 25

Wed, 26 Aug 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260826/26978274.html

Form 8-K Summit Therapeutics Inc. For: Aug 25

Wed, 26 Aug 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260826/26978274.html

Guggenheim Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

Wed, 26 Aug 2026 07:09:03 -0400

Guggenheim analyst Brad Canino reiterated a Buy rating and $38.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented: "Akeso announcing ivonescimab (PD-1xVEGF) beat a PD [L]1 inhibitor on a chemo backbone on ORR/PFS/OS in the China 1L BTC Phase 3 trial should add incremental confidence for the POS of SMMT's upcoming global 1L lung cancer Phase 3s. The current BTC standard of care is PD-[L]1 plus chemotherapy, which is the same as 1L lung, which was established in the TOPAZ-1 and KEYNOTE-966 trials. Phase 1/2 ivonescimab plus chemo data were superior cross trial to those benchmarks. However, the

H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)

Wed, 26 Aug 2026 06:40:16 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Neutral rating and {REMOVEPT} price target on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented: "Akeso’s 682-patient China Phase 3 HARMONi-GI1 study met the pre-specified interim OS endpoint for ivonescimab + gemcitabine/cisplatin (GemCis) vs. AstraZeneca’s durvalumab + GemCis, with PFS and ORR endpoints also met. Akeso disclosed no HRs, medians, event maturity, biliary tract cancer (BTC) subtype results or safety. The control is relevant: TOPAZ-1 produced mOS of 13.0 vs. 11.4 months (HR 0.75) and mPFS of 7.2 vs. 5.7 months (HR 0.75) for durvalumab + GemCis vs. GemCis alone, while KEYNOTE-966 produced

Akeso's ivonescimab beats durvalumab in biliary tract cancer trial

Tue, 25 Aug 2026 18:39:12 -0400

Summit Therapeutics Inc. (NASDAQ: SMMT) announced that its partner Akeso Inc. reported positive topline results from the Phase III HARMONi-GI1 study evaluating ivonescimab plus chemotherapy against durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC).

According to the press release, the study met its primary endpoint of overall survival (OS) at a pre-specified interim analysis, with the ivonescimab-based regimen achieving statistically significant superiority over the durvalumab-based regimen. The trial also met key secondary endpoints of progression-free survival and objective response rate.

HARMONi-GI1 is a single-region, multi-center trial conducted and sponsored by Akeso in China. All data

Akeso's ivonescimab beats durvalumab in biliary tract cancer trial

Tue, 25 Aug 2026 18:39:12 -0400

HARMONi-GI1 is a single-region, multi-center trial conducted and sponsored by Akeso in China. All data

StreetInsider.com News Articles

UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

Form 8-K Summit Therapeutics Inc. For: Sep 15

Summit ivonescimab shows consistent survival data across regions at WCLC

Summit ivonescimab shows consistent survival data across regions at WCLC

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

Form 8-K Summit Therapeutics Inc. For: Sep 13

Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer

Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer

Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study

Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy

Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy

Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy

Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy

UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)

Summit Therapeutics plc (SMMT) Reiterated at Overweight by Cantor Fitzgerald

Form 8-K Summit Therapeutics Inc. For: Aug 25

Form 8-K Summit Therapeutics Inc. For: Aug 25

Guggenheim Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)

Akeso's ivonescimab beats durvalumab in biliary tract cancer trial

Akeso's ivonescimab beats durvalumab in biliary tract cancer trial